ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.216,19
1,54%
S&P 500
5.977,75
0,59%
Dow Jones
42.780,90
0,11%
Euro vs US Dollar
1,03837
0,76%
Bitcoin
101.984,79
3,72%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) News

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:BMY
DatumZeitQuelleÜberschriftSymbolFirma
03/01/202512h59Business WireBristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare ConferenceNYSE:BMYBristol Myers Squibb Co
27/12/202423h37Business WireU.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2NYSE:BMYBristol Myers Squibb Co
23/12/202412h59Business WireBristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic ArthritisNYSE:BMYBristol Myers Squibb Co
23/12/202412h45Business WireBristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal CancerNYSE:BMYBristol Myers Squibb Co
19/12/202412h59Business WireBristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025NYSE:BMYBristol Myers Squibb Co
11/12/202422h17Business WireBristol Myers Squibb Announces Dividend IncreaseNYSE:BMYBristol Myers Squibb Co
09/12/202423h45Business WireBristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding PipelineNYSE:BMYBristol Myers Squibb Co
26/11/202412h59Business WireBristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare ConferenceNYSE:BMYBristol Myers Squibb Co
19/11/202412h59Business WireBristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research PlatformsNYSE:BMYBristol Myers Squibb Co
15/11/202414h23Business WireBristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal CancerNYSE:BMYBristol Myers Squibb Co
15/11/202412h59Business WireBristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid TumorsNYSE:BMYBristol Myers Squibb Co
12/11/202422h05GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsNYSE:BMYBristol Myers Squibb Co
11/11/202412h59Business WireBristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024NYSE:BMYBristol Myers Squibb Co
05/11/202423h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202423h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202423h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202423h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202423h00Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
31/10/202421h16Business WireBristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024NYSE:BMYBristol Myers Squibb Co
31/10/202411h59Business WireBristol Myers Squibb Reports Third Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
28/10/202411h59Business WireBristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024NYSE:BMYBristol Myers Squibb Co
03/10/202423h35Business WireU.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)NYSE:BMYBristol Myers Squibb Co
30/09/202413h00GlobeNewswire Inc.Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell TherapiesNYSE:BMYBristol Myers Squibb Co
28/09/202401h38Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsNYSE:BMYBristol Myers Squibb Co
27/09/202417h06Business WireBristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World SettingNYSE:BMYBristol Myers Squibb Co
27/09/202403h05Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsNYSE:BMYBristol Myers Squibb Co
18/09/202412h59Business WireNew Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple SclerosisNYSE:BMYBristol Myers Squibb Co
15/09/202414h55Business WireBristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced MelanomaNYSE:BMYBristol Myers Squibb Co
12/09/202412h59Business WireBristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024NYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Kürzlich von Ihnen besucht

NASDAQ
TSLA
Tesla
NYSE
KO
Coca Cola
NYSE
MRK
Merck
NASDAQ
NVDA
NVIDIA
AMEX
XLV
Health Care Select Sector
USOTC
BASFY
BASF (QX)
TG
DBK
Deutsche Bank
FX
EURGBP
Euro vs Sterling
TG
LHA
Deutsche Lufthansa
TG
DTE
Deutsche Telekom
CCOM
US100
US Tech 100
USOTC
ADDYY
Adidas (QX)
AMEX
SPY
SPDR S&P 500
TG
TUI1
Tui
NYSE
MCD
McDonalds
TG
MBG
MercedesBenz
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten